Literature DB >> 20118975

Chemotherapy: cisplatin combinations in cervical cancer-which is best?

David O Holtz, Charles J Dunton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20118975     DOI： 10.1038/nrclinonc.2009.220

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  6 in total

1.  Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.

Authors:  Harry J Long; Brian N Bundy; Edward C Grendys; Jo Ann Benda; D Scott McMeekin; Joel Sorosky; David S Miller; Lynne A Eaton; James V Fiorica
Journal:  J Clin Oncol       Date:  2005-05-23       Impact factor: 44.544

2.  Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.

Authors:  T Thigpen; H Shingleton; H Homesley; L Lagasse; J Blessing
Journal:  Cancer       Date:  1981-08-15       Impact factor: 6.860

3.  Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study.

Authors:  David H Moore; John A Blessing; Richard P McQuellon; Howard T Thaler; David Cella; Jo Benda; David S Miller; George Olt; Stephanie King; John F Boggess; Thomas F Rocereto
Journal:  J Clin Oncol       Date:  2004-08-01       Impact factor: 44.544

4.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

5.  Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.

Authors:  Bradley J Monk; Michael W Sill; D Scott McMeekin; David E Cohn; Lois M Ramondetta; Cecelia H Boardman; Jo Benda; David Cella
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

6.  A review of topotecan in combination chemotherapy for advanced cervical cancer.

Authors:  Minoo Robati; David Holtz; Charles J Dunton
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423
  6 in total
  1 in total

1.  Sound preconditioning therapy inhibits ototoxic hearing loss in mice.

Authors:  Soumen Roy; Matthew M Ryals; Astrid Botty Van den Bruele; Tracy S Fitzgerald; Lisa L Cunningham
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.